CV Therapeutics Reports 2007 Fourth Quarter and Full Year Financi...($- Basic and diluted net loss per...)

Basic and diluted net

loss per share,

non-GAAP(3) $(0.57) $(1.18) $(2.71) $(5.49)

Shares used in

computing basic and

diluted net loss

per share 59,696 57,823 59,335 49,983

(2) CVT believes that the non-GAAP financial measures presented in this

press release are useful for investors because these measures provide

added insight into CVT's performance by focusing on results generated

by its ongoing operations. In addition, CVT uses these non-GAAP

financial measures when assessing the performance of its ongoing

operations, in making resource allocation decisions and for planning

and forecasting.

(3) The values shown above are exact; totals may not appear to sum due to

rounding.

CONSOLIDATED BALANCE SHEET DATA

(in thousands)

(unaudited)

December 31, December 31,

2007 2006

Assets:

Cash, cash equivalents,

and marketable securities $174,245 $325,226

Other current assets 41,825 40,269

Total current assets 216,070 365,495

Property and equipment, net 19,131 23,919

Other assets 23,635 32,042

Total assets $258,836 $421,456

Liabilities and stockholders' deficit:

Current liabilities $39,183 $62,247

Convertible subordinated notes 399,500 399,500

Other long-term obligations 5,551 5,507